Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (509)	3/7/2005 7:55:21 AM
From: Icebrg	Read Replies (2) \| Respond to of 946

>>Put it in the non-binary file?>> For the time being, at least. It's really too early to tell what went wrong, if anything went wrong. If this was just a case of the trial being underpowered, there are another two studies to be unblinded before the half year mark. If there was indeed no treatment effect observed, we can just as well concentrate on Pixantrone in Q4. It's also very difficult to say what to make of the non-inferiority argument put forward by the company. The FDA has approved based on that recently (Abraxane and Alimta). But that is a tricky area, so one should perhaps not hope to much from that. The best hope for longs should be a classic case of too little power to prove the survival benefit. Then there should be a fair chance that one of the next two trials will do better. FDA's statisticians willing. I was pretty confident that there was going to be a positive outcome based on the survival, but I was evidently wrong on that count. Erik

To: tom pope who wrote (509)	3/7/2005 10:20:08 AM
From: nigel bates	Respond to of 946

Put it in the non-binary file? Given they have negative bv, I'd say they are still very much so - just a bit longer term.